Embecta to acquire Owen Mumford for up to £150M; adds drug-delivery platform

Embecta Corp.

Upfront cash payment of £100M at closing; up to £50M earnout based on Aidaptus net sales by end of 2028.
Owen Mumford generated £69.4M revenue in FY2025; transaction expected to close in Embecta's fiscal Q3 2026.
Deal unanimously approved by Embecta board; expected to be accretive to adjusted net income after FY2028.
Acquisition positions Embecta in drug-delivery devices for chronic care (obesity, diabetes, autoimmune, anaphylaxis).
Embecta plans to fund upfront with borrowings under its revolving credit facility.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Embecta Corp. entered into a asset purchase with Owen Mumford Holdings Limited valued at up to £150 million (effective 2026-03-19).

Action: entry
Agreement: asset purchase
Counterparty: Owen Mumford Holdings Limited
Value: up to £150 million
Effective: 2026-03-19

Exact text from the filing

hat it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies, in a transaction valued at up to £150 million.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Embecta Corp. filing history →

Source: SEC EDGAR

accession 0000947871-26-000310

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.